1. Scrip
  2. >>Business

What To Expect As IRA Legal Challenges Mount

US Chamber Of Commerce Suit Raises New Arguments

 
• By Jessica Merrill

A second lawsuit was filed against the IRA and a new US Medicare drug price negotiation program, and this time, the lawsuit was not filed by an industry insider. 

judge gavel
A second lawsuit was filed against the IRA • Source: Shutterstock

Just days after Merck & Co., Inc. filed the first lawsuit against the US government over the implementation of a new Medicare drug price negotiation program ordered under the Inflation Reduction Act (IRA), a second lawsuit was filed by the US Chamber of Commerce.

Key Takeaways
  • The US Chamber of Commerce filed a second lawsuit against the IRA.
  • A broad business organization like the chamber could help reframe the political dialogue around...

“I think we expected a lawsuit from the pharmaceutical industry, which is the most directly impacted by the law, but it is interesting to see a lawsuit from the Chamber...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.